Format

Send to

Choose Destination
PLoS One. 2018 Sep 13;13(9):e0202772. doi: 10.1371/journal.pone.0202772. eCollection 2018.

Treatment with placental growth factor attenuates myocardial ischemia/reperfusion injury.

Author information

1
Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
2
Department of Burn and Plastic Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan, China.

Abstract

Studies have established that oxidative stress plays an important role in the pathology of myocardial ischemia/reperfusion injury (MIRI). Vascular endothelial growth factor receptor 1 (VEGFR1) activation was reported to reduce oxidative stress and apoptosis. In the present study, we tested the hypothesis that the activation of VEGFR1 by placental growth factor (PlGF) could reduce MIRI by regulating oxidative stress. Mouse hearts and neonatal mouse cardiomyocytes were subjected to ischemia/reperfusion (I/R) and oxygen glucose deprivation (OGD), respectively. PlGF pretreatment markedly ameliorated I/R injury, as demonstrated by reduced infarct size and improved cardiac function. The protection was associated with a reduction of cardiomyocyte apoptosis. Similarly, our in vitro study showed that PlGF treatment improved cell viability and reduced cardiomyocyte apoptosis. Also, activation of VEGFR1 by PlGF suppressed intracellular and mitochondrial reactive oxygen species (ROS) generation. However, VEGFR1 neutralizing monoclonal antibody, which preventing PlGF binding, totally blocked this protective effect. In conclusion, activation of VEGFR1 could protect heart from I/R injury by suppression of oxidative stress and apoptosis.

PMID:
30212490
PMCID:
PMC6136704
DOI:
10.1371/journal.pone.0202772
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center